Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy
Y Kakeji, T Oshikiri, G Takiguchi, S Kanaji, T Matsuda… - Esophagus, 2021 - Springer
Esophageal cancer has a poor prognosis despite the fact that surgical techniques have
been advanced and optimized, and systemic multimodality approaches have progressed …
been advanced and optimized, and systemic multimodality approaches have progressed …
Role of imaging in esophageal cancer management in 2020: update for radiologists
OBJECTIVE. The purpose of this article is to discuss the role of imaging in the management
of esophageal cancer. CONCLUSION. A multimodality-based approach to imaging is …
of esophageal cancer. CONCLUSION. A multimodality-based approach to imaging is …
Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging
C Schmidkonz, S Rauber, A Atzinger… - Annals of the …, 2020 - ard.bmj.com
Objectives To date, there is no valuable tool to assess fibrotic disease activity in humans in
vivo in a non-invasive way. This study aims to uncouple inflammatory from fibrotic disease …
vivo in a non-invasive way. This study aims to uncouple inflammatory from fibrotic disease …
Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate …
S Schmuck, CA von Klot, C Henkenberens… - Journal of Nuclear …, 2017 - Soc Nuclear Med
A quantitative imaging biomarker is desirable to provide a comprehensive measure of whole-
body tumor burden in patients with metastatic prostate cancer, and to standardize the …
body tumor burden in patients with metastatic prostate cancer, and to standardize the …
68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre …
C Bergmann, JHW Distler, C Treutlein… - The Lancet …, 2021 - thelancet.com
Background Interstitial lung disease (ILD) is the most common cause of death in systemic
sclerosis. To date, the progression of systemic sclerosis-associated ILD is judged by the …
sclerosis. To date, the progression of systemic sclerosis-associated ILD is judged by the …
68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer
C Schmidkonz, M Cordes, D Schmidt, T Bäuerle… - European journal of …, 2018 - Springer
Purpose We aimed at evaluating the role of 68 Ga-PSMA-11 PET/CT-derived metabolic
parameters for assessment of whole-body tumor burden and its capability to determine …
parameters for assessment of whole-body tumor burden and its capability to determine …
A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [68Ga]Ga-PSMA-11 total-body PET/CT imaging
J Lv, H Yu, H Yin, Y Shi, H Shi - European Journal of Nuclear Medicine …, 2024 - Springer
Purpose To improve the diagnostic accuracy of initial detection in patients with suspected
primary prostate cancer (PCa). Methods Eighty-four patients who underwent Gallium-68 …
primary prostate cancer (PCa). Methods Eighty-four patients who underwent Gallium-68 …
Risk stratification of oesophageal squamous cell carcinoma using change in total lesion glycolysis and number of PET-positive lymph nodes
Background The efficacy of neoadjuvant chemotherapy (NACT) correlates with patient
survival in oesophageal squamous cell carcinoma (OSCC), but optimal evaluation of the …
survival in oesophageal squamous cell carcinoma (OSCC), but optimal evaluation of the …
Combining the radiomic features and traditional parameters of 18F-FDG PET with clinical profiles to improve prognostic stratification in patients with esophageal …
YH Chen, KH Lue, SC Chu, BS Chang… - Annals of Nuclear …, 2019 - Springer
Objectives To investigate the role of the traditional and radiomic parameters of 18 F-FDG
PET for predicting the outcomes of patients with esophageal squamous cell carcinoma …
PET for predicting the outcomes of patients with esophageal squamous cell carcinoma …
[HTML][HTML] Perioperative immunotherapy for esophageal squamous cell carcinoma: Now and future
Y Liu - World Journal of Gastroenterology, 2023 - ncbi.nlm.nih.gov
Esophageal cancer (EC) ranks among the most prevalent malignant tumors affecting the
digestive tract. Esophageal squamous cell carcinoma (ESCC) stands as the prevailing …
digestive tract. Esophageal squamous cell carcinoma (ESCC) stands as the prevailing …